MEDCL.PA Medincell SA

Healthcare Biotechnology Euronext Paris
28.44 EUR
Close of Nov 8, 2026
19.69 32.38
Market cap
EUR 1.02B
P/E
-
P/B
333.86x
ROE
-1,021.1%
Dividend yield
-
Fundamental score
1.5/5

Ratios use the latest price and the fiscal year ending Mar 2026.

Is MEDCL.PA undervalued?

Graham number

The Graham number of Medincell SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Medincell SA fundamental analysis

3 of 11 checks passed

ROE 2/2

The stock's ROE exceeds expectations (1196.41%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

ROA 0/2

The stock's ROA (-62.5%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 2/2

The stock's low PBV ratio (-11.16x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 2/2

The stock has a minimal amount of debt (-355%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Net Profit Growth 0/2

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Graham Number 0/1

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Buffet Intrinsic Value 0/1

Based on Warren Buffett's formula, the company's stock seems overpriced (-1), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Medincell SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Medincell SA

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, whi…

Full company profile